Author:
Sekine I,Nishiwaki Y,Kakinuma R,Kubota K,Hojo F,Matsumoto T,Ohmatsu H,Goto K,Kodama T,Eguchi K,Shinkai T,Tamura T,Ohe Y,Kunitoh H,Yoshimura K,Saijo N
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Ando M, Eguchi K, Shinkai T, Tamura T, Ohe Y, Yamamoto N, Kurata T, Kasai T, Ohmatsu H, Kubota K, Sekine I, Hojo N, Matsumoto T, Kodama T, Kakinuma R, Nishiwaki Y, Saijo N (1997) Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer. Br J Cancer 76: 1494–1499
2. Ardizzoni A, Antonelli G, Grossi F, Tixi L, Cafferata M, Rosso R (1999) The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC). Ann Oncol 10(Suppl 5): S13–S17
3. Armitage P, Berry G (1994) Survival Analysis. In Statistical Methods in Medical Research, 3rd edn, Armitage P, Berry G (eds) pp 469–492. Oxford: Blackwell Scientific Publications
4. Fukuoka M, Masuda N, Negoro S, Matsui K, Yana T, Kudoh S, Kusunoki Y, Takada M, Kawahara M, Ogawara M, Kodama N, Kubota K, Furuse K (1997) CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 75: 306–309
5. Fukuoka M, Nagao K, Ohashi Y, Niitani H (2000) Impact of irinotecan (CPT-11) and cisplatin (CDDP) on survival in previously untreated metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 19: 495a
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献